Thermo Fisher Scientific expands with state-of-the-art facility in China
Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients.
Thermo Fisher Scientific has announced that it will be opening a new facility for the development and manufacturing of biologics and steriles in Hangzhou, China.
The site will mean Thermo fisher are more well placed to address the needs of companies to give quicker access to therapies for patients in China and the Asia-Pacific region.
"Hangzhou is a strategic addition to our global pharma services network and the latest example of our commitment to meeting customer demands globally,” stated Mike Shafer, Senior Vice President and President, Pharma Services. “We continue to invest in capabilities to support the manufacturing needs of our customers, enabling them to serve more patients throughout the world.”
The cGMP facility will be 80,000 m2, offering integrated clinical and commercial drug type capabilities, from process development all the way to sterile fill-finish. In the future Thermo Fisher will expand these capabilities to include commercial packaging and labelling.
The facility will house the latest in technology, including Thermo Fisher 2,000-liter HyPerforma Single-Use Bioreactors and associated Single-Use equipment and this will expand to include bioreactor capacity up to 5,000 litres through Thermo Scientific DynaDrive technology in the future.
The manufacturing facility is hoping to set a precedent of quality control and good practices, with processes meeting and exceeding current regulations from the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration, and authorities in Europe and elsewhere.
“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research and pharma services businesses,” commented Hann Pang, President, Thermo Fisher China. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”
Thermo Fisher provides complete end-to-end contract development and manufacturing, the new site in Hangzhou demonstrates the global scale of this capability as well as ensuring the advanced delivery of medicine to patients.
Related News
-
News Biotheus partners with BioNTech to take their anti-tumour therapy global
Innovative biotech company Biotheus has signed a deal with BioNTech to manufacture, market, and distribute their latest anti-tumour therapy around the world. -
News Roche acquires rights to Zion Pharma's HER2-positive breast cancer therapeutic
Roche launches into a new agreement with Zion Pharma, a leading Chinese pharmaceutical company, to help develop and commercialise their flagship small molecule tyrosine kinase inhibitor, ZN-A-1041. -
News 2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ... -
News Lonza start commercial operations in newly expanded facility
Lonza Small Molecules adds new capabilities to their expanded facility in China, enabling smoother transitions between small and large scale manufacturing. -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News WuXi STA launches new HPAPI production facility in China
The new plant features flow chemistry and milling technology, as well as reactors up to 3,000 liters -
News Mitigating supply risk: Having feet on the ground during COVID-19
Having personnel on the ground may be central to mitigating supply chain risks, even as the world embraces the remote approach.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance